No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 7.8x · 10Y median 11.6x · 25th percentile · as of Sep 9, 2026
Annualized revenue (TTM) · by quarter, last 17
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-09-11T09:06:03.738Z. Latest historical point 2026-09-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Tempus AI, Inc. (TEM) stock was $58.74 as of Sep 10, 2026, 4:00 PM EDT, down 4.14% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -24.4%
Tempus AI, Inc. operates as a healthcare technology company in the United States.
Medical - Healthcare Information Services · Chicago, IL
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 3, 2026
53 days away
EPS Estimate
-0.07
Revenue Est.
$410.11M
Last Quarter Results
EPS
$-0.04
vs Estimate
$-0.15
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1TEM | $10.29B | $58.74 | -4.14% | -24.37% | N/A | N/A | N/A |
| 2MOH | $10.45B | $200.28 | +3.17% | +11.80% | -4.52% | +13.53% | vs TEM |
| 3UHS | $10.46B | $172.72 | -1.74% | -5.30% | +3.74% | +4.34% | vs TEM |
| 4ENSG | $10.07B | $172.79 | +0.60% | +4.15% | +16.88% | +25.02% | vs TEM |
| 5COO | $10.56B | $54.17 | -14.67% | -19.95% | -13.65% | +1.62% | vs TEM |
| 6HSIC | $9.94B | $87.30 | -0.76% | +29.53% | +2.61% | +3.43% | vs TEM |
N/A
$382.49M
vs Estimate
$379.69M
Consensus Rating
Based on 15 analysts
Average Price Target
$67.47
+14.9% upside
Low
$35.00
Current
$58.74
High
$100.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.08 | $-0.07 | $-0.07 | 8 |
| Quarter ending Dec 2026 | $-0.01 | $0.00 | $0.01 | 8 |
| Quarter ending Mar 2027 | $-0.10 | $-0.10 | $-0.10 | 3 |
| Quarter ending Jun 2027 | $-0.06 | $-0.05 | $-0.05 | 4 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.37 | $-0.20 | $-0.01 | 10 |
| FY 2027 | $-1.99 | $0.04 | $2.61 | 10 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $405.38M | $410.11M | $418.19M | 11 |
| Quarter ending Dec 2026 | $450.35M | $455.89M | $463.30M | 11 |
| Quarter ending Mar 2027 | $430.68M | $437.04M | $444.80M | 5 |
| Quarter ending Jun 2027 | $467.57M | $474.47M | $482.89M | 5 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.59B | $1.60B | $1.66B | 15 |
| FY 2027 | $1.89B | $1.97B | $2.05B | 15 |
